MedTrace Logo

The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy

NCT07721623 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2026-07-23

No results posted yet for this study

Summary

The uterine fibroids are the most common benign tumors found in the female reproductive system. Uterine fibroids commonly cause heavy menstrual periods. The prevalence of uterine fibroids is significantly affecting up to 70-80% of women by the age of 50, with an inconsistent impact on women of African origin. Carbitocin is a synthetic analogue of oxytocin which has a longer half-life than oxytocin. A Cochrane review and meta-analysis studies found that carbitocin reduced the use of additional uterotonics and transfusion. However, few of these studies was done during myomectomy.

Conditions

  • Blood Loss, Surgical

Interventions

DRUG

Carbetocin

Carbitocin is an oxytocid with longer half life

Sponsors & Collaborators

  • Alex Ekwueme Federal University Teaching Hospital

    lead OTHER

Principal Investigators

  • DARLINTON-PETER CHIBUZOR UGOJI, FELLOWSHIP · DAVID UMAHI FEDERAL UNIVERSITY TEACHING HOSPITAL UBURU, EBONYI STATE

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-15
Primary Completion
2028-08-14
Completion
2028-08-14

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07721623 on ClinicalTrials.gov